Mirum Pharmaceuticals, Inc. $MIRM is Patient Square Capital LP’s 10th Largest Position

Patient Square Capital LP decreased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 8.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 104,262 shares of the company’s stock after selling 9,200 shares during the quarter. Mirum Pharmaceuticals makes up 2.0% of Patient Square Capital LP’s investment portfolio, making the stock its 10th largest position. Patient Square Capital LP owned 0.20% of Mirum Pharmaceuticals worth $7,643,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. CWM LLC grew its stake in shares of Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the last quarter. Legal & General Group Plc lifted its holdings in Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after buying an additional 176 shares during the period. MCF Advisors LLC grew its position in shares of Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the last quarter. Teacher Retirement System of Texas increased its stake in shares of Mirum Pharmaceuticals by 2.2% during the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after buying an additional 215 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in shares of Mirum Pharmaceuticals by 34.0% during the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock valued at $70,000 after buying an additional 243 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Evercore restated an “outperform” rating and issued a $101.00 price objective on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. Citizens Jmp boosted their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research report on Friday, December 19th. Finally, TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $110.17.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron bought 131,425 shares of the firm’s stock in a transaction on Friday, January 23rd. The stock was acquired at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the completion of the purchase, the director owned 459,010 shares of the company’s stock, valued at approximately $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Joanne Quan sold 6,911 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total value of $623,855.97. Following the completion of the sale, the insider directly owned 11,305 shares in the company, valued at approximately $1,020,502.35. This represents a 37.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 45,136 shares of company stock valued at $4,352,029. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $105.16 on Monday. The company’s fifty day moving average price is $90.24 and its 200-day moving average price is $77.94. The stock has a market cap of $5.40 billion, a PE ratio of -122.28 and a beta of 0.49. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $107.41.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.